Perier-Muzet M, et al. - The purpose of this study was to investigate if age exerted an impact on the clinical outcome and immune adverse events in patients treated by immunotherapy for metastatic melanoma. A possible link was brought to light between age with a better clinical outcome after treatment with immunotherapy in the real-life scenario. More immune-related adverse events were not reported among older patients. In order to affirm the yielded data and to elucidate the underlying mechanisms, advanced studies were warranted.